Maria S Svane, Caroline C Øhrstrøm, Astrid Plamboeck, Nils B Jørgensen, Kirstine N Bojsen-Møller, Carsten Dirksen, Christoffer Martinussen, Tina Vilsbøll, Bolette Hartmann, Carolyn F Deacon, Viggo B Kristiansen, Filip K Knop, Lars B Svendsen, Sten Madsbad, Jens J Holst, Simon Veedfald
OBJECTIVE: Neurotensin (NT) is released from enteroendocrine cells and lowers food intake in rodents. We evaluated postprandial NT secretion in humans after surgeries associated with accelerated small intestinal nutrient delivery, and after Roux-en-Y gastric bypass (RYGB) when glucagon-like peptide-1 (GLP-1) signalling and dipeptidyl peptidase 4 (DPP-4) were inhibited, and during pharmacological treatments influencing entero-pancreatic functions. METHODS: We measured NT concentrations in plasma from meal studies: (I) after truncal vagotomy with pyloroplasty (TVP), cardia resection +TVP (CTVP), and matched controls (n = 10); (II) after RYGB, sleeve gastrectomy (SG), and in matched controls (n = 12); (III) after RYGB (n = 11) with antagonism of GLP-1 signalling using exendin(9-39) and DPP-4 inhibition using sitagliptin; (IV) after RYGB (n = 11) during a run-in period and subsequent treatment with, sitagliptin, liraglutide (GLP-1 receptor agonist), verapamil (calcium antagonist), acarbose (alpha glucosidase inhibitor), and pasireotide (somatostatin analogue), respectively...
January 2022: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society